MARINI, Stefano
 Distribuzione geografica
Continente #
NA - Nord America 232
EU - Europa 38
AS - Asia 27
SA - Sud America 2
Totale 299
Nazione #
US - Stati Uniti d'America 231
IN - India 19
UA - Ucraina 12
IT - Italia 10
CN - Cina 8
FI - Finlandia 7
SE - Svezia 4
AR - Argentina 2
GB - Regno Unito 2
IE - Irlanda 2
CA - Canada 1
NL - Olanda 1
Totale 299
Città #
Fairfield 34
Houston 30
Woodbridge 28
Chandler 20
Ashburn 15
Wilmington 13
Seattle 11
Beijing 8
Princeton 8
San Paolo di Civitate 8
Cambridge 7
Plano 7
Washington 6
Ann Arbor 4
Lawrence 4
Millbury 4
Jacksonville 3
San Diego 3
Boston 2
Dublin 2
Federal 2
Philadelphia 2
Rome 2
Boardman 1
Des Moines 1
Norwalk 1
Provo 1
Toronto 1
Totale 228
Nome #
A potent and selective inhibition of parainfluenza 1 (Sendai) virus by new 6-oxiranyl-, 6-methyloxiranyluracils, and 4(3H)-pyrimidinone derivatives 70
GROWTH INHIBITION OF FRIEND ERYTHROLEUKAEMIA CELL TUMOURS IN VIVO BY A SYNTHETIC ANALOGUE OF PROSTAGLANDIN A: AN ACTION INDEPENDENT OF NATURAL KILLER-ACTIVITY 65
Studies on the chemistry of pyrimidine derivatives with dimethyldioxirane: synthesis, cytotoxic effect and antiviral activity of new 5,6-oxiranyl-5,6-dihydro and 5-hydroxy-5,6-dihydro-6-substituted uracil derivatives and pyrimidine nucleosides 51
Synthesis, cytotoxic effect and antiviral activity of 1-(beta-D-arabinofuranosyl)-5-bromo-N4-substituted cytosine and 1-(beta-D-arabinofuranosyl)-5-bromo-4-methoxypyrimidin-2(1H)-one derivatives. 41
Growth inhibition of Friend erythroleukemia cell tumors in vivo by a synthetic analogue of PGA 34
Antiviral activity of new 6-Oxiranyl-, 6-Methyloxiranyluracils, and 4(3H)-Pyrimidinone derivatives. 26
Further evidences on the role of serotonin (5HT) on PRL secretion: effects of Ritanserin, specific 5HT-2 antagonist, administration 12
Totale 299
Categoria #
all - tutte 590
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 590


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201938 0 0 0 0 0 0 0 0 4 6 15 13
2019/202071 13 2 1 3 7 6 12 6 6 11 2 2
2020/202117 3 3 0 1 1 2 0 3 0 1 3 0
2021/202254 0 2 8 0 8 0 0 7 6 4 12 7
2022/202361 13 14 1 6 10 7 0 3 5 0 0 2
2023/202414 2 6 6 0 0 0 0 0 0 0 0 0
Totale 299